ANVS Stock Analysis: Buy, Sell, or Hold?
ANVS - Annovis Bio, Inc.
$1.70
-0.04 (-2.30%)
▼
5d:
-5.03%
30d:
-23.77%
90d:
-28.27%
HOLD
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ANVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ANVS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ANVS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ANVS is currently trading at $1.70, which is considered oversold relative to its 30-day fair value range of $1.74 to $2.02.
Technical Outlook: Technically, ANVS is in a strong downtrend. The price is currently testing key support at $1.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.50 (+618.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ANVS is in a strong downtrend. The price is currently testing key support at $1.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.50 (+618.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.74 -
$2.02
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 618.4% below Wall St target ($12.50)
- CAUTION: Recommendation downgraded due to -5.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.74 -
$2.02
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.52
(30.9%)
Support & Resistance Levels
Support Level
$1.69
Resistance Level
$1.90
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.50
Wall Street Target
$12.50
(+618.4%)
Share & Embed Analysis
Last updated: June 24, 2026 4:43 PM ET
Data refreshes hourly during market hours. Next update: 5:43 PM
Data refreshes hourly during market hours. Next update: 5:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANVS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael B Hoffman
BUY
713800 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 60 BUY |
